Navellier & Associates Inc Vertex Pharmaceuticals Inc Transaction History
Navellier & Associates Inc
- $805 Million
- Q1 2024
A detailed history of Navellier & Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Navellier & Associates Inc holds 11,861 shares of VRTX stock, worth $5.56 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
11,861
Previous 12,398
4.33%
Holding current value
$5.56 Million
Previous $5.04 Million
1.7%
% of portfolio
0.62%
Previous 0.76%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,623Shares Held
222MCall Options Held
1.35MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA25.6MShares$12 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$10.6 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$10.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.63 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.33 Billion1.08% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...